At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Sodium Benzoate +3 moredrug
Likely dose
Sodium Benzoate 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre 12-week Randomised Double-blind Placebo Controlled Feasibility Trial of Sodium Benzoate and/or N-acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
In Brief
A Phase 2 clinical trial evaluating Sodium Benzoate, N-Acetylcysteine, and 2 other interventions for Schizophrenia and 2 related conditions. Completed, enrolled 64 participants across 5 sites.
Detailed Summary
This study aims to determine if the addition of Sodium Benzoate and / or NAC to TAU will be acceptable and tolerable and result in overall improvement of symptoms, social and cognitive functioning in patients with early schizophrenia spectrum disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPakistan
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartJan 2019
Primary CompletionDec 2020
Study CompletionMar 2021
TodayJul 2026
First PostedApr 27, 2018
Enrollment StartJan 1, 2019
Primary CompletionDec 30, 2020
Study CompletionMar 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.2 years ago
Interventions
Sodium Benzoatedrug
Sodium Benzoate will be administered at 1000mg daily
N-Acetylcysteinedrug
N-Acetylcysteine 1000 mgs twice daily dose
Placebodrug
Placebo added to TAU
Sodium Benzoate Plus N-Acetylcysteinedrug
Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose